Analysis: Josh Gottheimer's purchase of GILD (Gilead Sciences, Inc.)
Assessment: On watch
Suspiciously timed purchase 24 hours before major Medicare pricing news, but likely diluted by the member's high-frequency trading baseline.
- Member: Josh Gottheimer
- Party / state: Democratic, NJ-5
- Chamber: Representatives
- Transaction: Purchase
- Amount: $1,001 - $15,000
- Ticker: GILD
- Company: Gilead Sciences, Inc.
- Trade date: 2026-01-27
- Disclosure date: 2026-02-26
- Disclosure lag: 30 days
Executive summary
Rep. Josh Gottheimer purchased GILD on 2026-01-27, a ticker he has traded infrequently compared to his high-volume tech holdings. The trade occurred within 48 hours of another purchase by Rep. Ro Khanna, suggesting a potential cluster of interest in the healthcare sector among House members.
The purchase of GILD at $140.97 follows a period of low activity in this specific ticker for Gottheimer, whose portfolio is heavily dominated by Information Technology (MSFT, AAPL, NVDA). Notably, another member (Ro Khanna) executed a larger purchase of the same ticker just two days later. While Gottheimer sits on Financial Services and Intelligence committees, which do not have direct jurisdiction over pharmaceutical regulation, the timing of the trade relative to other members and the shift away from his typical tech-heavy trading patterns are the most significant findings. Insider activity at the company showed minor selling shortly after the trade date.
Timeline
- 2026-01-27 — Josh Gottheimer purchases GILD ($1k-$15k)
- 2026-01-29 — Ro Khanna purchases GILD ($15k-$50k)
- 2026-02-26 — Trade disclosed to the public
Independent analysis of public financial disclosures. Not financial or investment advice.
Sources
- Josh Gottheimer
- Joshua Gottheimer Stock Trades & Portfolio | Congressional Trading Tracker
- Josh Gottheimer Trading Activity | Quiver Quantitative
- Representative Josh Gottheimer Latest Stock Trading - GuruFocus.com
- Track US politician stock trades
- Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
- Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
- Gilead stock dips as Medicare targets Biktarvy for 2028 price talks — and Trodelvy gets a guideline lift
- Dow Theory Letters - Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
- Lobbying Update: $30,000 of TIBER CREEK GROUP ON BEHALF OF GILEAD SCIENCES INC. lobbying was just disclosed | Quiver Quantitative